Axxam S.p.A., a leading provider of integrated early drug discovery services, has entered into a strategic collaboration with Molecular Health GmbH, a frontrunner in AI-powered biomedical data solutions. The partnership aims to accelerate the identification and validation of novel therapeutic targets across diverse disease areas, leveraging the combined power of computational insights and biological validation.
At the core of this collaboration is the integration of Molecular Health’s advanced digital drug development platform, Dataome, into DiscoveryMAXX, Axxam’s comprehensive early discovery platform. This fusion of technologies is designed to offer pharmaceutical and biotech companies precise, clinically informed disease-to-target and target-to-lead solutions, optimizing the path from early discovery to preclinical development.
Dataome curates, structures, and analyzes vast and complex datasets, including molecular, phenotypic, and clinical information sourced from public, private, and proprietary origins. By applying sophisticated AI algorithms, Molecular Health generates causal insights to help drug developers predict safety, identify high-potential targets, and design more effective clinical trials.
These AI-driven predictions will be seamlessly incorporated into Axxam’s robust biological discovery platform, which brings decades of expertise in biology, assay development, phenotypic and target-based screening, and compound profiling. Importantly, Axxam’s platform enables rigorous experimental validation of computational targets using cutting-edge in vitro models, including those based on induced pluripotent stem cells (iPSCs). This ensures that predicted targets are biologically and clinically relevant, improving translational outcomes.
“Identifying the right drug target remains one of the biggest challenges in discovery,” said Ciriaco Maraschiello, CEO of Axxam. “By combining our biology-driven validation expertise with Molecular Health’s AI capabilities, we’re enabling faster, more informed decision-making in early-stage drug development.”
Friedrich von Bohlen, CEO of Molecular Health, echoed this sentiment, stating, “Understanding the molecular basis of disease is key to improving drug development success. This partnership allows us to integrate our AI-powered data insights with Axxam’s deep biological know-how to deliver better results, faster.”
Together, Axxam and Molecular Health are creating a new model for early drug discovery—one that combines digital intelligence with biological depth to deliver smarter, faster, and more reliable outcomes for clients across the global life sciences sector.